Getting a Second Opinion on Adrenal Cancer

A service at U-M helps provide a second opinion for those diagnosed with adrenal cancer. Here’s how to get it — and who is eligible.

8:00 AM

Author | Susan Daron, R.N.

Adrenal cancer is rare, affecting around 1,000 patients per year in the United States. Because of its rarity, though, not all hospitals or doctors are experienced in identifying and treating it.

The Remote Second Opinion Program at the University of Michigan Rogel Cancer Center, which includes a multi-specialist tumor board review of medical records, radiological images and pathological specimen and/or reports, helps provide an extra layer of scrutiny.

For a $900 fee, patients diagnosed with or suspected to have adrenal cancer can send in their medical records, radiology studies and, if available, tumor tissue. After those materials are reviewed, the patient and their own doctor will be contacted by phone and may have a consultation with an expert in U-M's Multidisciplinary Endocrine Oncology Clinic

The conversation usually takes place about one week after a case file is reviewed.

Although it is always best to see a doctor in person, the supplemental service — available to domestic and international patients — could be of particular help for those unable to travel to Michigan due to a physical ailment or financial hardship.

There are some caveats, however: The Remote Second Opinion Program has several restrictions. It isn't covered by health insurance plans, including Medicare and Medicaid, and it requires approval from the patient's current doctor.

Residents of the following states are excluded from participation due to legal reasons: California, Iowa, Louisiana, Maine, New York, North Dakota, South Carolina, Tennessee and Wyoming.

And the review process can only be utilized once; any subsequent discussions with a U-M expert must take place in person.

To learn more about the Remote Second Opinion Program for adrenal cancer, call the U-M Cancer AnswerLine at 800-865-1125 (available Monday to Friday from 8 a.m. to 5 p.m. Eastern Standard Time).

More Articles About: Cancer Care Adrenal Cancer Metabolism, Endocrinology & Diabetes
Health Lab word mark overlaying blue cells
Health Lab

This article is from the Health Lab digital publication.

Media Contact Public Relations

Department of Communication at Michigan Medicine



Get a weekly digest of medical research and innovation, straight to your inbox.

Featured News & Stories
Health Lab
Do unto others
Tina Reuben was the first patient in one of the few clinical trials for adrenal cancer and hopes that her involvement can help other patients with the rare disease live longer.
Food blood vial collage
Health Lab
Blood-based metabolic signature outperforms standard method for predicting diet, disease risk
The study found that machine learning techniques improved diet prediction by 10-20%.
woman in forest looking with binoculars
Health Lab
How a clinical trial expanded options for a patient with a rare cancer
A rare bile duct cancer was difficult to treat once it spread to the lining of Lori Robertson’s abdomen. A clinical trial, led by University of Michigan Health, gave her some other options.
Health Lab
Lipids in blood predict nerve damage risk among patients with type 2 diabetes
The findings open up potential to test for biomarkers and facilitate more focused management of patients with the condition.
man taking photo with camera at camera
Health Lab
The ups and downs of stage 4 cancer
Scott Ward’s been through it all: hormone therapy, chemotherapy, radiation, surgery, genetic sequencing, group therapy and more. Now, he’s channeling the roller coaster of his cancer treatment into art.
scientists in goggles gloves looking at specimen in lab
Health Lab
Changing the treatment of cancer
Breakthroughs in the field of genomics are revolutionizing prevention, diagnosis and care.